OSR Health (OSRHW) Net Equity Issued and Repurchased (2023 - 2026)

OSR Health (OSRHW) posted Net Equity Issued and Repurchased of $844885.6 for Q1 2026, down 40.14% sequentially from $1.4 million in Q4 2025.

OSR Health (OSRHW) Net Equity Issued and Repurchased (2023 - 2026) Analysis & Trends

OSR Health has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $844885.6 in Q1 2026.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $844885.6 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (changed N/A YoY) and the FY2025 annual result came in at $4.8 million, changed N/A from the prior year.
Net Equity Issued and Repurchased eased to $844885.6 in Q1 2026 per OSRHW's latest filing, from $1.4 million in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $9.2 million in Q1 2023 and troughed at $844885.6 in Q1 2026.
A 3-year average of $3.8 million and a median of $1.4 million in 2025 frame the typical range for Net Equity Issued and Repurchased.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	138.97 Bn	131.12 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.15 Bn	77.15 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	62.84 Bn	57.65 Bn	1.37 Bn	-
4	Moderna	55.74 Bn	50.60 Bn	52.00 Mn	-
5	BeOne Medicines	41.53 Bn	36.43 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.60 Bn	28.29 Bn	992.69 Mn	-
7	BioNTech SE	27.32 Bn	8.93 Bn	668.28 Mn	-
8	Royalty Pharma	27.29 Bn	26.45 Bn	-	-
9	Insmed	26.99 Bn	25.83 Bn	358.27 Mn	-
10	OSR Health	1.40 Mn	20.39 Mn	86,605.00	1.26 Mn

Download Data